RBC
TBPH icon

Roble Belko & Company’s Theravance Biopharma TBPH Stock Holding History

Roble Belko & Company’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-714
Closed -$26K – 415
2016
Q3 		$26K Hold
714
– – 0.01% 145
2016
Q2 		$16K Buy
+714
New +$15.4K 0.01% 167

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Roble Belko & Company's TBPH Position: Q4 2016 in Review

Roble Belko & Company sold out of Theravance Biopharma (TBPH) in Q4 2016, closing a stake of 714 shares — an estimated $26K sold.

Roble Belko & Company first reported a position in TBPH in Q2 2016 and held it in 2 quarters. The position peaked at $26K in Q3 2016. 98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

  • Roble Belko & Company reported no remaining Theravance Biopharma position as of Q4 2016 after selling out during the quarter.
  • Roble Belko & Company sold 714 Theravance Biopharma shares in Q4 2016, an estimated $26K.
  • Roble Belko & Company first reported a position in Theravance Biopharma in Q2 2016 and held it in 2 quarters.
  • Roble Belko & Company's Theravance Biopharma position peaked at $26K in Q3 2016.
  • 98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on Roble Belko & Company's 13F filing for Q4 2016, filed 18 Jan 2017.